Labcorp Holdings Inc. has announced the expansion of its precision oncology portfolio, introducing new test offerings for solid tumors and hematologic malignancies. The company has also enhanced its biopharma solutions to accelerate clinical trials and companion diagnostic development. Labcorp is now offering the Labcorp Plasma Focus, a solid tumor liquid biopsy test, in Geneva, Switzerland, and Shanghai, China. This is part of a global expansion to complement the Labcorp Tissue Complete, a tissue-based comprehensive genomic profiling assay for pan-solid tumors. Additionally, Labcorp has launched new NGS panels for myeloid, lymphoid, and pan-heme indications, and a Rapid AML Panel to improve treatment decisions for acute myeloid leukemia. The company is also expanding its capabilities to include homologous recombination deficiency testing in its OmniSeq INSIGHT pan-solid tumor profiling test.